GlassScriptPhysician profile
Henna S Shah
NPI 1629517925
$8,566.11
in general payments reported to CMS, 2019-2025
30 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $669 · 2022: $1,203 · 2023: $1,492 · 2024: $3,215 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,082 · Education: $362 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,081.95 |
| Education | $362.28 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,664.11 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $696.26 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $553.18 | 2021-2025 | Cabtreo, Arazlo, Duobrii |
| Janssen Biotech, INC. | $504.46 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $490.18 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $479.64 | 2023-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $382.17 | 2023-2025 | Zoryve |
| Epi Health, LLC | $336.66 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $331.95 | 2021-2025 | Winlevi |
| Verrica Pharmaceuticals INC. | $324.18 | 2023-2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $304.84 | 2023-2025 | Sotyktu |
| Incyte Corporation | $297.38 | 2023-2024 | Opzelura |
| Genzyme Corporation | $270.37 | 2021-2024 | |
| Journey Medical Corporation | $257.86 | 2022-2025 | |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $231.32 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $222.18 | 2022-2025 | Nemluvio, Aklief |
| Organon LLC | $174.16 | 2024-2025 | Hadlima, Vtama |
| Amgen INC. | $162.03 | 2023-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $139.03 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $137.51 | 2021-2025 | |
| Leo Pharma INC. | $121.23 | 2023-2025 | Adbry, Anzupgo |
| Ucb, INC. | $68.75 | 2022-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.25 | 2025 | Acthar |
| Boston Scientific Corporation | $16.51 | 2022 | |
| Kerecis Limited | $15.77 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $15.71 | 2024 | |
| Blueprint Medicines Corporation | $14.60 | 2024 | Ayvakit |
| Almirall LLC | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henna Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.